Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2Lymphoid 1

Conditions

Myelodysplastic Syndromes 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia 7Leukemia, Myeloid, Acute 6Medulloblastoma 5Lymphoma 5Sarcoma 4Hematologic Neoplasms 4Central Nervous System Neoplasms 4Brain Neoplasms 4Astrocytoma 4Rhabdoid Tumor 3Ovarian Neoplasms 3Glioma 3Ependymoma 3Burkitt Lymphoma 3Anemia, Refractory, with Excess of Blasts 3Wilms Tumor 2Rhabdomyosarcoma 2Retinoblastoma 2Primary Myelofibrosis 2Pinealoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Liver Neoplasms 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Cytarabine 30fludarabine phosphate 13Etoposide 12Cyclophosphamide 11Mitoxantrone 10Peripheral Blood Stem Cell Transplantation 9Decitabine 9Tacrolimus 7Filgrastim 7Mycophenolic Acid 6Bortezomib 6Idarubicin 5Flow Cytometry 5Daunorubicin 5Antilymphocyte Serum 5tipifarnib 4sargramostim 4Whole-Body Irradiation 4Vorinostat 4Radiotherapy 4Cyclosporine 4Cord Blood Stem Cell Transplantation 4Clofarabine 4Busulfan 4alvocidib 3Polymerase Chain Reaction 3Melphalan 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3tanespimycin 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Congenital Abnormalities × Thiotepa × Clear all
NCT00376480 2019-07-05

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Dana-Farber Cancer Institute

Phase 1 Completed
19 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes

NCT00104975 2016-12-15

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Yale University

Phase 1 Completed
20 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Burkitt Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡